Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Abuse Deterrent Formulation Science Meeting

A discussion about the Food and Drug Administration’s draft guidance for industry: “Abuse Deterrent Opioids – Evaluation and Labeling,” will be heldSeptember 30-October 1, 2013. The discussion is part of the Abuse Deterrent Formulation Science meeting, being held at the Bethesda North Marriott Conference Center, in Bethesda, Md.

The meeting is organized by the Cross-Company Abuse Liability Consortium and facilitated with the aid of the College on Problems of Drug Dependence. The Safety Pharmacology Society is also sponsoring the meeting. The meeting is being convened to provide an open forum to foster discussion and recommendations about the draft guidance.

Presentations will be given by an international group of academicians, industry representatives, and FDA staff. In addition to formal presentations, several panels will discuss the following topics from draft guidance: laboratory manipulation and extraction studies; pharmacokinetic and clinical abuse potential studies; and postmarketing studies and drug labeling.

The registration fee is $500.

See link below for more information:

Page Last Updated: 04/19/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English